Search | Clinical Trials Finder

Conditions: Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Interventions: autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452; Biological · Device
Lead sponsor: Daniel Bauer; Other
Eligibility: 13 Years to 40 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hyperbilirubinemia, Jaundice
Interventions: Gene mutation sample; Procedure
Lead sponsor: Pediatrix; Other
Eligibility: Up to 6 Days
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Acute Chest Syndrome, Sickle Cell Disease
Interventions: Point of Care Ultrasound; Device
Lead sponsor: Indiana University; Other
Eligibility: Up to 25 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Sickle Cell Disease
Interventions: Hydromorphone (Standardized, weight-based dosing), Morphine Sulfate (Standardized, weight-based dosing), Hydromorphone (Patient Specific dosing), Morphine Sulfate (Patient Specific dosing); Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: New York, New York • Cincinnati, Ohio

Conditions: Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia
Interventions: iodine I 131 monoclonal antibody BC8, total-body irradiation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, fludarabine phosphate, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis; Radiation · Procedure · Drug + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 50 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sickle Cell Disease
Interventions: Ticagrelor, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Miami, Florida • Bethesda, Maryland • Charleston, South Carolina

Conditions: Sickle Cell Anemia, Sickle Cell β+ or β0 Thalassemia
Interventions: Not listed
Lead sponsor: HaEmek Medical Center, Israel; Other
Eligibility: 1 Year to 40 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Transfusional Iron Overload, Thalassemia Major, Sickle Cell Disease, Myelodysplastic Syndromes, Aplastic Anemia
Interventions: Hepatic biomagnetic susceptibility measurement; Device
Lead sponsor: Columbia University; Other
Eligibility: 5 Years to 80 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Fetomaternal Hemorrhage, Neonatal Anemia
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: Up to 60 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease
Interventions: Deferoxamine, Deferasirox, Deferiprone, Echocardiography, Electrocardiogram (ECG); Drug · Device
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Fairfax, Virginia • Falls Church, Virginia

Conditions: Sickle Cell Disease, Thalassemia, Marrow Aplasia
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Sickle-Cell Disease With Crisis
Interventions: sublingual sufentanil; Drug
Lead sponsor: Jason Wilson; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Fanconi Anemia
Interventions: Specimen Donation; Diagnostic Test
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Woburn, Massachusetts

Conditions: Sickle Cell Anemia, Sickle Cell Disease, Hemoglobin Disorder
Interventions: Metformin, Questionnaires; Drug · Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 60 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
Interventions: CTX001; Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
Interventions: antitumor drug screening assay, chemotherapy, biological therapy; Other · Drug · Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Beta-thalassemia, Iron Overload
Interventions: Deferasirox; Drug
Lead sponsor: Novartis; Industry
Eligibility: 10 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Los Angeles, California • Oakland, California • Chicago, Illinois

Conditions: Sickle Cell Disease
Interventions: ketamine; Drug
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 7 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Farmington, Connecticut • Hartford, Connecticut

Conditions: Anemia, Sickle Cell
Interventions: NP Battery, MRI; Behavioral · Procedure
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 21 Years to 55 Years
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 12
States / cities: Los Angeles, California • Oakland, California • Hollywood, Florida + 8 more

Conditions: Sickle Cell Disease
Interventions: Alemtuzumab, Total Body Irradiation, Sirolimus; Drug · Radiation
Lead sponsor: Kathleen Dorritie; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sickle Cell Crisis, Sickle Cell Disease
Interventions: Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sickle Cell Disease, Asthma, Acute Chest Syndrome
Interventions: Budesonide inhalation suspension; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 1 Year to 4 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia
Interventions: cytarabine, idarubicin, tipifarnib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 15 Years to 70 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sickle Cell Disease
Interventions: massage, relaxation; Procedure · Behavioral
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 15 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 2
States / cities: Los Angeles, California • Tampa, Florida

Search by objective public record fields.

Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease

Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia

Ultrasound Acute Chest Syndrome Sickle Cell Disease

Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease

Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease

Sickle Cell Anemia - A Comparative Study Between Three Ethnical Communities, a Multicenter Study

High-Tc Susceptometer to Monitor Transfusional Iron Overload

Identification of Early Predictors of Fetomaternal Hemorrhage

Early Screening and Treatment of Heart Complication in Sickle Cell Disease

Genes Influencing Iron Overload State

DSUVIA in Patients With SCD VOC Present in the ED

Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia

Fetal Hemoglobin Induction Treatment Metformin

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment

Low-Dose Ketamine Infusion for Children With Sickle Cell Disease-Related Pain

Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease

Stem Cell Transplant in Patients With Severe Sickle Cell Disease

Mindfulness and Yoga Therapy for Acute Pain in Sickle Cell Disease

Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial

Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia

Home Based Massage and Relaxation for Sickle Cell Pain